Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ff283c7d6797987f01db547f606e6b32 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57484 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
filingDate |
2016-07-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_92e646c5872dcd484a1c3d07955adf48 |
publicationDate |
2018-02-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
KR-20180013556-A |
titleOfInvention |
The diagnosis bio-marker predicting prostate cancer metastasis and the therapeutic composition suppressing metastasis of castration-resistant prostate cancer |
abstract |
The present invention relates to a diagnostic biomarker composition capable of predicting metastasis of prostate cancer and a therapeutic composition for inhibiting metastasis in hormone refractory prostate cancer. The present invention is a composition for treating prostate cancer comprising shRNA or siRNA corresponding to the ccm1 gene to inhibit expression of CCM1 protein. The present invention also provides a composition for treating prostate cancer, which comprises DDX5 protein as an active ingredient. According to the present invention, it is possible to provide a composition which can be used as a diagnostic biomarker capable of predicting the onset of cancer progression along with the appearance of hormone refusal. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022169342-A3 |
priorityDate |
2016-07-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |